TOP TEN perturbations for 38990_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38990_at
Selected probe(set): 212987_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38990_at (212987_at) across 6674 perturbations tested by GENEVESTIGATOR:
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):3.753213Number of Samples:4 / 4
Experimental | B-CLL study 11 (rolipram) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
Control | rolipram study 4 (normal B-cell; 20uM) |
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):3.339634Number of Samples:4 / 4
Experimental | B-CLL study 11 (DMSO) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
Control | vehicle (DMSO) treated normal B-cell sample |
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
omeprazole study 6 (600uM) / vehicle (DMSO) treated hepatocyte sample
Relative Expression (log2-ratio):-3.1834145Number of Samples:2 / 2
Experimental | omeprazole study 6 (600uM) |
Hepatocytes treated with compound: omeprazole (600uM; CHEMBL1503) for 24 hours. ATC code: | |
Control | vehicle (DMSO) treated hepatocyte sample |
Hepatocytes treated with vehicle (DMSO) for 24 hours. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-2.9756851Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
sulindac study 5 (3000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.9248972Number of Samples:2 / 2
Experimental | sulindac study 5 (3000uM) |
Hepatocytes treated with compound: sulindac (3000uM; CHEMBL15770) for 24 hours. ATC code: | |
Control | vehicle (medium) treated hepatocyte sample |
Hepatocytes treated with vehicle (medium) for 24 hours. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-2.602581Number of Samples:4 / 6
Experimental | F. tularensis study 1 (novicida) |
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-2.5662355Number of Samples:4 / 6
Experimental | F. tularensis study 1 (tularensis Schu S4) |
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
sickle cell disease study 2 (Pax) / normal blood sample
Relative Expression (log2-ratio):2.5048409Number of Samples:5 / 5
Experimental | sickle cell disease study 2 (Pax) |
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion step. | |
Control | normal blood sample |
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit followed by an on-column DNase digestion step. |
sickle cell disease study 2 (Globin red.) / normal blood sample
Relative Expression (log2-ratio):2.3656483Number of Samples:5 / 5
Experimental | sickle cell disease study 2 (Globin red.) |
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclear™-Human kit. | |
Control | normal blood sample |
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit including an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclearTM-Human kit. |
omeprazole study 5 (600uM) / vehicle (DMSO) treated hepatocyte sample
Relative Expression (log2-ratio):-2.3504477Number of Samples:2 / 2
Experimental | omeprazole study 5 (600uM) |
Hepatocytes treated with compound: omeprazole (600uM; CHEMBL1503) for 8 hours. ATC code: | |
Control | vehicle (DMSO) treated hepatocyte sample |
Hepatocytes treated with vehicle (DMSO) for 8 hours. |